JP2019521179A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521179A5
JP2019521179A5 JP2019515776A JP2019515776A JP2019521179A5 JP 2019521179 A5 JP2019521179 A5 JP 2019521179A5 JP 2019515776 A JP2019515776 A JP 2019515776A JP 2019515776 A JP2019515776 A JP 2019515776A JP 2019521179 A5 JP2019521179 A5 JP 2019521179A5
Authority
JP
Japan
Prior art keywords
composition
weight
concentration
asparaginase
polyalkylene oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019515776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521179A (ja
JP7109427B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/035461 external-priority patent/WO2018017190A2/en
Publication of JP2019521179A publication Critical patent/JP2019521179A/ja
Publication of JP2019521179A5 publication Critical patent/JP2019521179A5/ja
Priority to JP2022030538A priority Critical patent/JP7857767B2/ja
Application granted granted Critical
Publication of JP7109427B2 publication Critical patent/JP7109427B2/ja
Priority to JP2025181444A priority patent/JP2026016612A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019515776A 2016-06-01 2017-06-01 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 Active JP7109427B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022030538A JP7857767B2 (ja) 2016-06-01 2022-03-01 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法
JP2025181444A JP2026016612A (ja) 2016-06-01 2025-10-28 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662344252P 2016-06-01 2016-06-01
US201662344249P 2016-06-01 2016-06-01
US201662344256P 2016-06-01 2016-06-01
US62/344,252 2016-06-01
US62/344,249 2016-06-01
US62/344,256 2016-06-01
PCT/US2017/035461 WO2018017190A2 (en) 2016-06-01 2017-06-01 Formulations of polyalkylene oxide-asparaginase and methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022030538A Division JP7857767B2 (ja) 2016-06-01 2022-03-01 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法

Publications (3)

Publication Number Publication Date
JP2019521179A JP2019521179A (ja) 2019-07-25
JP2019521179A5 true JP2019521179A5 (enExample) 2020-06-18
JP7109427B2 JP7109427B2 (ja) 2022-07-29

Family

ID=60992770

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019515776A Active JP7109427B2 (ja) 2016-06-01 2017-06-01 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法
JP2022030538A Active JP7857767B2 (ja) 2016-06-01 2022-03-01 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法
JP2025181444A Pending JP2026016612A (ja) 2016-06-01 2025-10-28 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022030538A Active JP7857767B2 (ja) 2016-06-01 2022-03-01 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法
JP2025181444A Pending JP2026016612A (ja) 2016-06-01 2025-10-28 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法

Country Status (32)

Country Link
US (3) US12343387B2 (enExample)
EP (3) EP4778589A2 (enExample)
JP (3) JP7109427B2 (enExample)
KR (3) KR102783452B1 (enExample)
CN (1) CN109640961B (enExample)
AU (1) AU2017299374B2 (enExample)
BR (1) BR112018074823B1 (enExample)
CA (1) CA3026070A1 (enExample)
CL (1) CL2018003418A1 (enExample)
CO (1) CO2018013753A2 (enExample)
CY (1) CY1124980T1 (enExample)
DK (1) DK3463308T4 (enExample)
ES (1) ES2905874T5 (enExample)
FI (1) FI3463308T4 (enExample)
HR (1) HRP20212027T4 (enExample)
HU (1) HUE057856T2 (enExample)
IL (2) IL312621A (enExample)
LT (1) LT3463308T (enExample)
MX (2) MX388814B (enExample)
MY (1) MY198474A (enExample)
PH (1) PH12018502540A1 (enExample)
PL (1) PL3463308T5 (enExample)
PT (1) PT3463308T (enExample)
RS (1) RS62979B2 (enExample)
RU (1) RU2758796C2 (enExample)
SA (1) SA518400557B1 (enExample)
SG (1) SG11201810685WA (enExample)
SI (1) SI3463308T2 (enExample)
SM (1) SMT202200049T1 (enExample)
UA (1) UA123020C2 (enExample)
WO (1) WO2018017190A2 (enExample)
ZA (2) ZA201807943B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018150196A1 (en) 2017-02-17 2018-08-23 Oxford University Innovation Limited Cell penetrating peptides modified by glycosylation
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
WO2020089743A1 (en) 2018-11-02 2020-05-07 Cadila Healthcare Limited Pharmaceutical composition of pegylated l-asparaginase
AU2019394177A1 (en) 2018-12-07 2021-06-10 Oxford University Innovation Limited Linkers
EA202191646A1 (ru) * 2018-12-24 2022-01-14 Дженнова Биофармасьютикалз Лимитед Лиофилизированная композиция пегаспаргазы
CA3211038A1 (en) 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
KR20230165799A (ko) * 2021-04-06 2023-12-05 재즈 파마슈티칼즈 아일랜드 리미티드 L-아스파라기나제의 제제
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法
CN119326875A (zh) * 2024-12-23 2025-01-21 中国人民解放军总医院第三医学中心 L-ASNase在制备治疗膀胱癌药物中的应用及试剂盒

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2433883C2 (de) * 1973-07-20 1986-03-27 Research Corp., New York, N.Y. Verwendung von physiologisch aktiven Polypeptiden
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3279834D1 (en) * 1981-12-31 1989-08-31 Asta Pharma Ag 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression
JPS58183626A (ja) 1982-04-21 1983-10-26 Nippon Oil Co Ltd 白血病治療用ｌ−アスパラギナ−ゼ固定化剤
US4729957A (en) 1984-12-13 1988-03-08 The United States Of America As Represented By The Department Of Health And Human Services Process for manufacture of L-asparaginase from erwinia chrysanthemi
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ATE300519T1 (de) * 1989-04-19 2005-08-15 Enzon Inc Verfahren zum herstellen von modifizierten polypeptiden die eine polypeptid und ein polyalkylenoxid enthalten
GB9017002D0 (en) 1990-08-02 1990-09-19 Health Lab Service Board Improved method for the purification of erwina l-asparaginase
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
TW197439B (enExample) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
AU4242993A (en) 1992-05-21 1993-12-13 Penn State Research Foundation, The Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US6277828B1 (en) 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US6087151A (en) 1995-02-08 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo DNA coding for mammalian L-asparaginase
EP0831100B1 (en) 1995-04-21 2000-10-11 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6537547B1 (en) 1996-06-07 2003-03-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Polypeptides having L-asparaginase activity
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
ZA983497B (en) 1997-04-28 1999-10-25 Lilly Co Eli Activated protein c formulations.
EP0988050B1 (en) 1997-06-09 2004-04-28 Childrens Hospital Of Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
US6991788B1 (en) 1997-06-09 2006-01-31 Childrens Hospital Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
IL133585A0 (en) 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
US5854051A (en) 1997-09-15 1998-12-29 Heska Corporation Parasitic helminth asparaginase proteins, nucleic acid molecules, and uses thereof
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
CA2324467C (en) 1998-03-26 2002-11-05 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
EP1820516B1 (en) 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
CA2475738A1 (en) 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7910661B2 (en) * 2003-01-06 2011-03-22 Nektar Therapeutics Thiol-selective water-soluble polymer derivatives
CN101484181B (zh) 2006-06-30 2012-12-26 希格马托罕见疾病公司 用于生产l-天门冬酰胺酶ⅱ的重组宿主
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
AU2008240796A1 (en) 2007-04-20 2008-10-30 Dsm Ip Assets B.V. Asparaginase enzyme variants and uses thereof
FI20070455A0 (fi) 2007-06-08 2007-06-08 Reagena Ltd Oy Menetelmä syöpäsairauksien tai tulehdussairauksien hoitoon
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
JP6045493B2 (ja) 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼａのｃｎｓ送達の方法および組成物
US9322008B2 (en) 2010-09-01 2016-04-26 Indian Institute Of Technology Mutants of L-asparaginase
RU2441914C1 (ru) 2010-10-06 2012-02-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича РАМН (ИБМХ РАМН) Способ получения субстанции рекомбинантной l-аспарагиназы erwinia carotovora
CN102138909B (zh) 2010-12-30 2013-03-13 常州千红生化制药股份有限公司 门冬酰胺酶冻干粉针剂及其制备方法以及门冬酰胺酶溶解液
US9051561B2 (en) 2011-10-10 2015-06-09 Children's Hospital Los Angeles Asparaginase and treating diseases associated with asparagine dependence
CN102657852A (zh) * 2012-05-22 2012-09-12 范铭琦 重组沃氏菌天门冬酰胺酶药物组合物及其制备法和应用

Similar Documents

Publication Publication Date Title
RU2018146395A (ru) Препараты полиалкиленоксид-аспарагиназы и способы их получения и применение
JP2022071060A5 (enExample)
RU2010114042A (ru) Применение пептида в качестве терапевтического средства
RU2010113969A (ru) Применение trp-6-трипторелина и d-leu6-лейпролида в качестве терапевтических средств
JP2009531275A5 (enExample)
US10806783B2 (en) Vaccine compositions
Lueth et al. Nanotherapeutic provides dose sparing and improved antimicrobial activity against Brucella melitensis infections
RU2010114051A (ru) Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств
RU2010113986A (ru) Применение пептида в качестве терапевтического средства
US20230051846A1 (en) Composition Comprising PIC For Treatment Of Cancer
EP2119451A1 (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
JP5179521B2 (ja) ペグ‐インターフェロンアルファ接合体および凍結保護剤としてラフィノースを含む組成物
Kouroussis et al. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study
JP2014504613A5 (enExample)
CN101732705A (zh) 用于治疗烈性肠道传染病的含霍乱毒素疫苗的制剂
NZ749069B2 (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
NZ788906B2 (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
CN114948944A (zh) 含有硫酸舒欣啶和胺碘酮的组合物在制备治疗心律失常药物中的应用
RU2024125372A (ru) Фармацевтические композиции для лечения недостаточности кислой сфингомиелиназы
Pavlovsky et al. Management of acute leukaemias
CHEN et al. The efficacy and safety of liver decanoic sulfonic sodium in the treatment of elderly patients with acute coronary syndrome
CN108066290A (zh) 一种真空发泡工艺制备甘草多糖冻干粉的方法
Manal M et al. Vinorelbine, 5 fluorouracil and folinic acid [fufol-nav] versus paclitaxel [p] as first line treatment in metastatic breast cancer patients pre-treated with anthracycline
Wasan et al. Response to Banaszkiewicz and Radzikowski
HK40007007B (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same